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Abstract
Background: Ivermectin, a substrate of multidrug resistance (MDR1) gene and cytochrome P450 (CYP) 3A4, has been 
used successfully in the treatment of onchocerciasis in Ghana. However, there have been reports of suboptimal 
response in some patients after repeated treatment. Polymorphisms in host MDR1 and CYP3A genes may explain the 
observed suboptimal response to ivermectin. We genotyped relevant functional polymorphisms of MDR1 and CYP3A 
in a random sample of healthy Ghanaians and compared the data with that of ivermectin-treated patients with a view 
to exploring the relationship between suboptimal response to ivermectin and MDR1 and CYP3A allelic frequencies.
Methods: Using PCR-RFLP, relevant polymorphic alleles of MDR1 and CYP3A4 genes were analysed in 204 randomly 
selected individuals and in 42 ivermectin treated patients.
Results: We recorded significantly higher MDR1 (3435T) variant allele frequency in suboptimal responders (21%) than 
in patients who responded to treatment (12%) or the random population sample (11%). CYP3A4*1B, CYP3A5*3 and 
CYP3A5*6 alleles were detected at varied frequencies for the sampled Ghanaian population, responders and 
suboptimal responders to ivermectin. CYP3A5*1/CYP3A5*1 and CYP3A5*1/CYP3A5*3 genotypes were also found to be 
significantly different for responders and suboptimal responders. Haplotype (*1/*1/*3/*1) was determined to be 
significantly different between responders and suboptimal responders indicating a possible role of these haplotypes in 
treatment response with ivermectin.
Conclusion: A profile of pharmacogenetically relevant variants for MDR1, CYP3A4 and CYP3A5 genes has been 
generated for a random population of 204 Ghanaians to address the scarcity of data within indigenous African 
populations. In 42 patients treated with ivermectin, difference in MDR1 variant allele frequency was observed between 
suboptimal responders and responders.
Background
P-glycoprotein (P-gp), a product of multidrug resistance
gene (MDR1), is a member of the adenosine triphos-
phate-binding cassette (ABC) membrane transporter
family. It is widely recognised as a component in the dis-
position of a large number of drugs [1,2]. P-gp is normally
located in tissues with excretory (liver, kidney) and bar-
rier (intestine, blood-brain, blood-testis blood-ovarian,
and placenta) functions [3-5]. P-gp acts as a protective
barrier to keep toxic substances out of the body and pre-
vent the accumulation of drugs in sensitive organs. Sev-
eral studies have identified genetic polymorphisms
within the MDR1 gene with altered P-gp expression levels
and functionality in tissues as well as effects on drug
response and clinical outcomes [6,7]. These polymor-
phisms have been reported in different ethnic popula-
tions and at varying allele frequencies [8]. The silent/
synonymous polymorphism has been associated with
reduction in P-gp levels in homozygous variant individu-
als and higher peak plasma concentrations of some drugs
e.g. the P-gp substrate digoxin in healthy individuals [7].
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For instance, the c.3435C > T polymorphism has been
associated with increased risk of diseases such as renal
tumor, Crohn's disease, ulcerative colitis and HIV infec-
tion [8]. Published results from studies using other P-gp
substrates in ethnically different populations were ambig-
uous with some researchers confirming lower P-gp
expression in 3435TT homozygote individuals and others
contradicting this observation [8,9]. The c.3435C > T
polymorphism in exon 26 has been demonstrated by
multiple studies to be in linkage disequilibrium with a
c.2677G > T/A polymorphism in exon 2, which suggests
that a haplotype effect may be responsible for the
observed functional P-gp effects. Recent studies have
suggested haplotypes of MDR1 as the main determinant
o f  f u n c t i o n a l  d i f f e r e n c e s  r a t h e r  t h a n  s i n g l e  n u c l e o t i d e
polymorphisms (SNPs) [10].
P-gp substrates and inhibitors can also be substrates for
Cytochrome P450 (CYP) enzymes. There are 18 families
of CYPs, which are divided further into 44 subfamilies
consisting of 57 genes [11]. CYP3A is one of the subfami-
lies co-expressed with P-gp in the liver and intestine with
overlapping substrate specificity [12]. The CYP3A gene
has been extensively studied in industrialised populations
because of its involvement in metabolism of many phar-
maceutical and recreational drugs. The CYP3A4 and
CYP3A5 enzymes are the two predominant isoforms of
the CYP3A subfamily expressed in the human liver, small
intestine, jejunum, colon, and pancreas [13-16].
Both CYP3A4 and CYP3A5 genes are polymorphic
with variant alleles generally occurring at low frequencies
in different ethnic groups [17]. CYP3A4*1B variant which
leads to amino acid change resulting in altered function,
has been associated with a number of clinical pheno-
types, including prostate cancer, leukaemia in individuals
treated with epipodophyllotoxin [18] and the early onset
of puberty [18-20]. CYP3A4*3 also leads to an amino acid
change, but available data suggests there is no significant
difference between the CYP3A4*3 variant and the wild-
type enzymes in the metabolism of testosterone, proges-
terone or 7-benzyloxy-4(trifluoromethyl) coumarin [21].
Several SNPs have also been reported for CYP3A5 gene
which impact enzyme function. CYP3A5*3  and
CYP3A5*6  variant alleles has been reported to cause
alternative splicing and blocks the production of proteins,
resulting in either a reduction or absence of CYP3A5
enzyme activity [14,22]. The presence of specific poly-
morphic alleles for CYP3A5 has been associated with
increases in blood pressure and incidence of myocardial
infarction [22].
Ivermectin (IVM), an anthelmintic drug, is a safe and
effective drug approved for the control of onchocerciasis
[23]. IVM is a known substrate for both the MDR1 and
the CYP3A4 genes which probably act synergistically to
reduce its oral absorption in susceptible individuals [24].
Human onchocerciasis is a vector borne disease that
causes blindness through infestation by a filarial nema-
tode (Onchocerca volvulus) transmitted by the black fly
(Simulium damnusum). The blindness and severity of
lesions caused by the parasite have serious socio-eco-
nomic impact in Ghana and other affected countries.
Treatment of the disease involves multiple annual treat-
ments with IVM typically for more than 7 years [25]. IVM
has been in use in Ghana for over 15 years for treatment
of onchocerciasis; however, there are emerging reports of
suboptimal response to IVM treatment in several individ-
uals as seen by the observation of high microfilaria load
in these patients despite many years of treatment [26].
This resistance can be due to the drug product, the host
or the parasite. Factors such as drug quality and formula-
tion, poor drug absorption, alcohol intake, varied metab-
olism and drug-drug interactions may underline the
suboptimal response to ivermectin treatment [26,27].
Genetic polymorphisms can cause pharmacokinetic vari-
ability which may also be responsible for the observed
suboptimal response. The host and the parasite do have
MDR1 and CYP3A genes and some workers have postu-
lated that parasite MDR1 gene may be contributing
towards drug inefficacy [28]. W e consider host genetic
factors also plausible to the apparent drug inefficacy and
thus suitable for pharmacogenetic consideration by
analysing the extent of variant alleles in responders and
subresponders to ivermectin treatment. This forms the
basis for the current study.
The aims of this study were:
1) To genotype relevant variants of MDR1, CYP3A4
and CYP3A5 genes in a random Ghanaian population to
address scarcity of data in indigenous African popula-
tions.
2) To explore the influence of genetic variations within
MDR1, CYP3A4 and CYP3A5 on response to ivermectin
treatment by examining genotype frequencies in
responders and suboptimal responders.
Methods
Subjects
Ethical approval for the study was obtained from the eth-
ics committees of the University of Portsmouth, Univer-
sity of Ghana Medical School and the Onchocerciasis
Chemotherapy Research Center (OCRC) in Hohoe,
Ghana. Written informed consents were obtained from
all subjects prior to inclusion in the study. Blood sample
(1 mL) was taken from 204 healthy unrelated blood
donors from Accra, Ghana of which 92 were males and
112 were female. In addition, 42 samples from equal
numbers of responders and suboptimal responders to
IVM were obtained from OCRC in Hohoe, Ghana. Ali-
quots of blood (500 μL) were spotted and preserved on
Whatman FTA cards (Fisher Scientific, UK) for analysis.Kudzi et al. BMC Medical Genetics 2010, 11:111
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DNA samples
Genomic DNA was extracted from 2 mm discs cored
from blood spotted FTA cards following the manufac-
turer's protocol. Briefly, the discs were incubated for 5
min in 200 μL FTA purification reagent. This washing
procedure was repeated three times in total for FTA
reagent and two times for buffer TE. The discs were dried
at 56°C for 10 min [29].
Genotyping
MDR1 variant alleles, c.1236C > T, c.2677G > A, c.2677G
> T and c.3435C > T, were separately analysed for the
random population and IVM treated patients using the
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) assay as described previously
by Cascorbi et al [30] and by Ameyaw et al [31].
CYP3A4*1B, CYP3A4*3, CYP3A5*3 and CYP3A5*6 vari-
ant alleles were also analysed by methods described by
van Schaik et al [32].
Statistical analysis
Allele and genotype frequencies of all polymorphisms
investigated were determined by SNPAlyze version 5.1
(Dynacom Co. Ltd., Yokohama, Japan). Genotype devia-
tions from the Hardy-Weinberg equilibrium and haplo-
type frequencies were also determined. Allele frequencies
of the random sample of Ghanaians were compared with
patients with a known IVM treatment history using a
Fisher's Exact Test (FET). A P-value ≤ 0.05 was consid-
ered significant.
Results and discussion
Study Population
Allele and genotype frequencies obtained for MDR1 and
CYP3A variants in the random sample of Ghanaians are
summarised in Table 1. Although a total of 204 samples
were collected for analysis, between 194 and 203 were
available for each SNP. The major allele was defined as
the most commonly occurring allele in the population.
All subjects were homozygous wildtype for both MDR1
exon 12 (C/C) and MDR1 exon 21 (G/G). None of the
subjects carried an MDR1 variant allele for either exon 12
(1236T) or exon 21 (2677T/A). Homozygous wildtype (C/
C) for exon 26 was found in 163 subjects (84%) in the
studied population. Heterozygote (C/T) individuals car-
rying one variant allele were detected in 38 subjects (19%)
while 3 individuals (2%) had homozygous variant (T/T)
allele. The frequencies of the wildtype allele (C) and the
variant allele (T) were found to be 89% and 11% respec-
tively.
Allele frequencies for CYP3A4*1B,  CYP3A5*3  and
CYP3A5*6 variants were observed at 72%, 15% and 14%
respectively (Table 1). Homozygous wildtype (*1/*1) was
found in 15 individuals (7%) while 86 (42%) were
heterozygous (*1/*1B) and 102 (50%) were homozygous
mutant (*1B/*1B) for CYP3A4*1B. The CYP3A4*3 variant
allele was not detected among the population studied. For
the  CYP3A5*3  allele, homozygous wildtype (*1/*1),
heterozygous (*1/*3) and homozygous variant (*3/*3) fre-
quencies were 70.5%, 29% and 0.5% respectively. Individ-
uals found with the wildtype (*1/*1) genotype were 141
(73%), 51 (26%) were heterozygous (*1/*6) and 2 (1%)
were recessive for the CYP3A5*6 variant allele (Table 1).
Recent studies have shown that haplotype analysis of
MDR1 may be more predictive of the changes in drug
response than individual SNPs [33-35]. Haplotypes were
determined for MDR1 across exons 12, 21 and 26. Two
haplotypes, C-G-C and C-G-T, were observed at 89% and
11% respectively (Figure 1). Haplotypes were also deter-
mined for SNPs genotyped within the CYP3A4 and
CYP3A5 genes. Seven haplotypes were observed promi-
nent among which were haplotypes 1 (*1B/*1/*1/*1), 2
(*1/*1/*1/*1) and 5 (*1B/*1/*1/*6) at 52.6%, 18.6%, and
13.0% respectively (Figure 2). Haplotypes 3 and 4 were
observed at 6.0% and 8.3%, respectively. Haplotypes 1
(*1B/*1/*1/*1) and 2 (*1/*1/*1/*1) may be associated with
normal expression of CYP3A proteins while haplotypes 3,
4 and 5 may be linked to the reduced CYP3A protein
expression. The reduced expression of haplotypes 3, 4
and 5 may be associated with reduced CYP3A4 activity.
Ivermectin-treated patients
The MDR1, CYP3A4 and CYP3A5 allele frequency distri-
bution in IVM-treated patients is summarised in Table 2.
Twenty one patients documented as having high microfi-
laria after many rounds of IVM treatment were classified
as suboptimal responders. These were matched with 21
other patients who respondered to IVM treatment and
were classified as responders. No variant allele was
detected for MDR1 exons 12 and 21 in either responders
or suboptimal responders. The MDR1 exon 26 variant
allele (3435T) frequency was detected at 12% in respond-
ers and at 21% in suboptimal responders. The most com-
mon genotype, wildtype (C/C), was detected in both the
responders and the suboptimal responders at 76% and
57% respectively. The heterozygous, (C/T), genotype fre-
quency was detected at 24% in the responders and 43% in
the suboptimal responders. These genotypic differences
in frequency between responders and suboptimal
responders were statistically significant (p < 0.01, FET).
The small sample size of ivermectin-treated individuals
(n = 42) is a limitation of this study and calls for caution
in making broad generalisations based on the results of
this study alone.
The  CYP3A4*1B,  CYP3A5*3, and CYP3A5*6  variant
allelic frequencies were found to be 60%, 31%, 7% for
responders and 31%, 21%, 12% for suboptimal responders
(Table 2). The CYP3A4*1B variant was the only signifi-Kudzi et al. BMC Medical Genetics 2010, 11:111
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cantly different allele among these two phenotypes (p <
0.001, FET). The CYP3A4*3  variant allele was not
detected in either of the two phenotypes investigated.
Seven genotypes were detected for the CYP3A alleles
analysed, but only two genotypes; CYP3A5*1/CYP3A5*1
and  CYP3A5*1/CYP3A5*3, were significantly different
between responders and suboptimal responders (p < 0.01,
FET).
Haplotypes were estimated for responder and subopti-
mal responder phenotypes across MDR1, CYP3A4 and
CYP3A5 variant alleles with emphasis on the combina-
tion of variant alleles which may be more likely to predict
changes in IVM response than the individual variant
alleles. The most frequent MDR1 haplotype (C-G-C) was
found in 16 individuals (88%) of responders as compared
to 12 individuals (79%) of suboptimal responders. Haplo-
type (C-G-T) was observed in 5 (12%) and 9 (21%) indi-
viduals of responders and suboptimal responders (Figure
1). Although haplotype data for MDR1 polymorphism
did not demonstrate significant difference between
Table 1: Allele and Genotype frequencies for the MDR1 and CYP3A observed in Ghanaian population (%, 95% CI in 
parenthesis)
MDR1 3435C > T CYP3A4*1B CYP3A5*3 CYP3A5*6
Total no genotyped 194 203 200 194
Major allele 153 15 141 141
homozygous (78.9, 73.1 - 84.6) (7.4, 3.79 - 11.0) (70.5, 64.1 - 76.8) (72.7, 66.4 - 79.0)
Heterozygous 38 86 58 51
(19.6, 14 - 25.2) (42.4, 35.6 - 49.2) (29, 22.7 - 35.3) (26.3, 20.1 - 32.5)
Minor allele 3 102 1 2
homozygous (1.6, -0.19 - 3.3) (50.3, 43.4 - 57.1) (0.05, -0.5 - 1.5) (1.03, -0.4 - 2.5)
Major allele 89 28 85 86
frequency (84.6 - 93.4) (21.8 - 34.2) (80.1 - 90.0) (81.1 - 90.9)
Minor allele 11 72 15 14
frequency (6.6 - 15.4) (65.8 - 78.2) (10.1 - 20.0) (9.1 - 18.9)
CI, Confidence interval. MDR1 (1236C > T), MDR1 (2677G > A), MDR1 (2677G > T), CYP3A4*3 variant alleles were not detected in this study 
population
Figure 1 Haplotype comparison of MDR1 allele frequency in RES, 
SOR and POP. Comparison of POP and RES data did not show any signif-
icant differences for haplotypes C-G-C and C-G-T. RES verses SOR; haplo-
type(CGT) POP = Random Ghanaian population, RES = responders, SOR = 
Suboptimal responders.
*
Figure 2 Haplotype comparison of CYP3A4 and CYP3A5 allele 
frequency in RES, SOR and POP. * p < 0.05; FET. RES verses SOR; hap-
lotype 4 (*1/*1/*3/*1) was significantly different POP = Random Ghanaian 
population, RES = responders, SOR = Suboptimal responders.
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Table 2: Allele and Genotype frequencies for the MDR1 and CYP3A observed in IVM treated subjects (%, 95% CI in parenthesis)
MDR1 3435C > T CYP3A4*1B CYP3A5*3 CYP3A5*6
RES SOR RES SOR RES SOR RES SOR
T o t a l  n o  g e n o t y p e d 2 12 12 12 12 12 12 12 1
Major allele 16 12 3 1 9 13 18 17
homozygous (76, 57.3 - 94.3) (57, 35.9 - 78.2) (14, -0.8 - 28.8) (5, -4.3 - 14.3) (43, 21.8 - 64.2) (62, 41.2 - 82.8) (86, 71.2 - 100) (81, 62.4 - 97.8)
Heterozygous 5 9 11 11 11 7 3 3
(24, 5.7 - 42.3) (43, 21.8 - 64.2) (53, 31.7 - 74.4) (52, 3.6 - 73.4) (52, 30.6 - 73.4) (33, 12.9 - 53.1) (14, -0.8 - 28.8) (14, -0.8 - 28.8)
M i n o r  a l l e l e 00791101
homozygous (33, 12.9 - 53.1) (43, 21.8 - 64.2) (5, -4.3 - 14.3) (5, -4.3 - 14.3) (5, -4.3 - 14.3)
Major allele 18 17 8 14 14 17 20 18
frequency (88, 74.1 - 101) (79, 61.6 - 96.4) (40, 19.1 - 61) (69, 49.2 - 88.8) (69, 49.2 - 88.8) (79, 61.6 - 96.4) (93, 82.1 - 103 (88, 74.1 - 101)
Minor allele 3 4 13 7 7 4 1 3
frequency (12, -1.9 - 25.9) (21, 3.6 - 38.4) (60, 30.1 - 81) (31, 11.2 - 50.8) (31, 11.2 - 50.8) (21, 3.6 - 38.4) (7, -3.9 - 17.9) (12, -1.9 - 25.9)
CI, Confidence interval. MDR1 (1236C > T), MDR1 (2677G > A), MDR1 (2677G > T), CYP3A4*3 variant alleles were not detected in this study populationKudzi et al. BMC Medical Genetics 2010, 11:111
http://www.biomedcentral.com/1471-2350/11/111
Page 6 of 8
responders and suboptimal responders (p = 0.127, FET),
individuals with (C-G-T) haplotype were more likely to
be suboptimal responder.
F i v e  h a p l o t y p e s  w e r e  d e t e c t e d  f o r  CYP3A4  and
CYP3A5  variant alleles. Haplotypes 1 (*1B/*1/*1/*1), 2
(*1/*1/*1/*1), 3 (*1B/*1/*3/*1), 4 (*1/*1/*3/*1) and 5 (*1B/
*1/*1/*6) were observed at a frequency of 36.4%, 25.5%,
16%, 15% and 7.1% for responders and 44.4%, 24.7%, 15%,
4%, and 9.5% for suboptimal responder respectively (Fig-
ure 2). No significant difference was detected between
responders and suboptimal responders for haplotypes 1
(*1B/*1/*1/*1), 2 (*1/*1/*1/*1), 3 (*1B/*1/*3/*1) and 5
(*1B/*1/*1/*6). However, significant difference was
observed between responders and suboptimal responders
for haplotype 4 (*1/*1/*3/*1), (p = 0.014; FET).
The haplotype frequencies of MDR1, CYP3A4  and
CYP3A5 of responders and suboptimal responders were
compared with data from the random population of 204
Ghanaians. MDR1 haplotypes observed for responders
and suboptimal responders were not significantly differ-
ent from the rest of the Ghanaian population (Figure 1).
Significant differences were observed between respond-
ers and the random Ghanaian population for haplotypes
1 (*1B/*1/*1/*1) and 3 (*1B/*1/*3/*1) (p < 0.05, FET). Dif-
ferences were also observed between suboptimal
responders and the random population for haplotype 3
(*1B/*1/*3/*1) (p < 0.05, FET). The differences between
the normal population, responders and suboptimal
responders for the rest of the haplotypes were not statisti-
cally significant (Figure 2). The difference between
responders and the random population for haplotypes 1
and 3 as well as between the suboptimal responders and
the random population for haplotype 3 indicates an
unclear relationship between these haplotypes and
response to ivermectin treatment. A more extensive
study is therefore required to delineate the contribution
of these haplotypes to response to ivermectin treatment.
The MDR1 gene is polymorphic with the frequency of
the T variant allele often associated with a decrease in P-
gp activity [7]. Although the 3435T variant in exon 26 has
previously been reported among the Ghanaian popula-
tion (17%) [31], it was detected at 11% in this study. The
present study has extended the characterisation to poly-
morphisms within exon 12 and exon 21. The 1236T vari-
ant in exon 12 and the 2677T variant in exon 21 were not
detected in this study but these have been reported in the
Beninese population at 15% and 1% respectively [36].
The  CYP3A4*1B  variant allele, associated with the
decrease of CYP3A4 activity, was detected at 71% in this
study which is comparable to the result of a previous
study within a random Ghanaian population (69%) [37].
This data is also similar to the incidence levels within
other African populations (69-82%) [38,39]. CYP3A4*1B
variant allele has scarcely been reported in the Caucasian
population (4-9%) [37,39] and has not been detected in
the Asian population [40]. The CYP3A4*3 variant was not
detected in this study, neither was it detected in an earlier
study among an undefined African population. It has
been reported in only 2% of Caucasian populations [39].
The  CYP3A5*3  variant allele was detected at a fre-
quency of 15% in this study population which was consis-
tent with data from an undefined African population
[39].  CYP3A5*3  variant was very commonly reported
among the Caucasian population (~93%) [41,39,42] and
was fairly common within Asian populations (60-76%)
[3,40]. The incidence of the CYP3A5*6 variant allele fre-
quency at 14% in this study was in agreement with
reported frequencies within other studies among an
undefined African population (16%) [39] and African
Americans (13%-16%) [41]. The CYP3A5*6 variant allele
was rarely reported among Caucasian populations [41]
and was not detected in the Asian population [40].
IVM has been in use in Ghana over the past 15 years to
treat onchocerciasis and has drastically improved the
health, social and economic well being of the people in
onchocerciasis-endemic areas [43]. IVM is a substrate of
both MDR1 [12] and CYP3A4 [17] which are localised
and expressed in the human liver and intestine and may
act either individually or synergistically with other agents
to influence its metabolism. However, these genes are
found in both the parasite and the host. The MDR1 gene
has been implicated in resistance to IVM and related
drugs in parasitic nematodes [44]. A study of the genetic
profile of microfilaria from these IVM treated suboptimal
responder patients showed changes in the allelic patterns
and a significant reduction in diversity at many of the loci
within the MDR1 of the parasite. This may have resulted
in a selection pressure on the MDR1 gene leading to the
development of the suboptimal responders [28]. Whilst
this study has indicated the possibility of the parasite
genes being implicated in suboptimal response to ivermc-
tin when used to treat onchocerciasis [28], no study has
been undertaken to show the impact of host genes on the
observed response.
In this study, MDR1,  CYP3A4 and CYP3A5 relevant
variants were analysed in the random sample from the
normal population as well as in responders and subopti-
mal responders to ivermectin treatment. Allele frequency
distribution and haplotype data for MDR1 in the random
p o p u l a t i o n  s a m p l e  w e r e  c o m p a r a b l e  w i t h  t h a t  o f
responder phenotypes. However, significant genotype
differences were observed between responders and sub-
optimal responders. The suboptimal responders were
twice as likely to be carriers of the 3435T variant allele.
CYP3A5*1/CYP3A5*1 and CYP3A5*1/CYP3A5*3 gen-
otypes were found to be significantly different for
responders and suboptimal responders. Individual
patients with homozygote wildtype (CYP3A5*1/Kudzi et al. BMC Medical Genetics 2010, 11:111
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CYP3A5*1) genotype are more likely to be suboptimal
responders while those with the heterozygote
(CYP3A5*1/CYP3A5*3)  genotype were less likely to be
suboptimal responder. The combine effect of the two
genotypes will lead to more CYP3A5 enzymatic activity
among suboptimal responders and less enzyme activity in
responders.
There were no statistically significant difference
between responders and suboptimal responders for a
majority of the haplotypes for CYP3A4 and CYP3A5. The
only exception was haplotype 4 (*1/*1/*3/*1). The impact
of this haplotype on IVM metabolism is not clear.
Although IVM is not a substrate of CYP3A5, the lower
frequency distribution of the CYP3A5*3 variant within
the suboptimal responders may be important since it has
been reported to be in linkage with CYP3A4*1B variant.
These polymorphisms have been reported to impact on
bioavailability and systemic clearance of MDR1 and
CYP3A4 substrates [45]. The CYP3A4*1B and CYP3A5*3
variants have been reported to be in linkage and a haplo-
type of these variants has been associated with prostate
cancer [19] and hypertension [22]. Interindividual varia-
tion in MDR1, CYP3A4 and CYP3A5 expression has also
been linked with possible variations in CD4 count and
antiretroviral efficacy in HIV treatment [46] and with dis-
eases such as prostate cancer [47] and hypertension [22].
Conclusion
Variant allele frequencies of pharmacogenetically-rele-
vant genes of MDR1 and CYP3A were determined in a
random Ghanaian population. Whilst a relationship
between MDR1 and CYP3A4 variants and response to
IVM treatment appear to have been established, the sam-
ple numbers for responders and suboptimal responders
were small. A larger study is necessary to confirm these
findings and utilise pharmacogenetics to optimise treat-
ment.
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